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Background: Polycystic ovarian syndrome (PCOS) is a low-grade inflammatory disease characterized by
hyperandrogenemia, hirsutism, chronic anovulation and vascular disorder. Interleukin-6 (IL-6), cyclooxygenase-2
(COX-2) and vascular endothelial growth factor (VEGF) are triggered by inflammatory stimuli and lead to angiogenesis
and pathogenesis of the ovary. Honeybee venom (HBV) contains an array of biologically active components possessing
various pharmaceutical properties. This study was designed to assess the possibility of HBV application as an
anti-inflammatory therapeutic agent to suppress levels of the main inflammatory mediators IL-6, COX-2 and VEGF.
To induce PCOS, 1 mg of estradiol valerate (EV) per 100 g of body weight was subcutaneously (SC) injected into
eight-week-old rats. After 60 days, 0.5 mg/kg of HBV was administered Intraperitoneal (IP) for 14 consecutive days,
and the results of PCOS treatment were investigated. Rats were then anesthetized with CO2, and the ovaries were sur-
gically removed. Serum IL-6 was detected by the ELISA kit. Immunoexpression of COX-2 and VEGF were examined in
three groups: EV-induced PCOS, HBV-treated PCOS and control animals.
Results: Thickness of theca layer, number and diameter of cysts and levels of IL-6 significantly decreased in HBV group
relative to PCOS group. The immunohistochemical analysis showed an increase in COX-2 and VEGF expression in PCOS
group whereas HBV-treated rats presented weak and irregular immunostaining.
Conclusions: Our results suggest that the beneficial effect of HBV may be mediated through its inhibitory effect on
serum IL-6 level and ovarian COX-2 and VEGF expression.
Keywords: Polycystic ovarian syndrome, Honeybee venom, Interlukin-6, Cyclooxygenase-2, Vascular endothelial
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Polycystic ovarian syndrome (PCOS), one of the most
common causes (70%) of anovulatory infertility, affecting
6% of women of reproductive age, is introduced as a
low-grade chronic inflammation [1]. Even though the
term PCOD is used for this disorder, PCOS is more
common, due to its heterogeneous clinical signs such as
hirsutism, hyperandrogenism and ovarian histopathological
disorders. Histological features of ovaries in PCOS include
the presence of more than 12 follicles smaller than 10 mm,
surrounding the stroma, and an increase in the thickness* Correspondence: devbiokharazmi@gmail.com
Department of Cell and Molecular Biology, School of Biological Sciences,
Kharazmi University, Karaj, Iran
© 2013 Karimzadeh et al.; licensee BioMed Ce
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumof follicular theca and the ovarian stroma volume, which
may be due to neoangiogenesis and vascular endothelial
growth factor (VEGF) expression in the ovary [1,2].
VEGF is a mediator of the cyclical growth of blood
vessels that occurs in the female reproductive tract [3,4].
Furthermore, VEGF is widely distributed in normal and
malignant tissue and is highly expressed in areas of
active vascular proliferation [5]. Unlike other growth
factors, the mitogenic activity of VEGF is restricted to
vascular endothelial cells. Increased expression of VEGF
has been described recently in hyperthecosis of polycystic
ovaries [2,6].
Cyclooxygenase-2 (COX-2) causes a decline in prostanoid
biosynthesis and is involved in inflammation, cell growth,ntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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http://www.jvat.org/content/19/1/32and specialization. COX-2 is induced by mitogens, growth
factors, cytokines, and tumor promoters [7]. Human
diseases that exhibit proliferative activity, inhibition of
apoptosis and neoangiogenesis have shown COX-2 over-
expression [8]. COX-2 plays an important role in
inflammation by prostaglandin synthesis. Nonsteroidal
anti-inflammatory drugs (NSAIDs) are anti-inflammatory
agents acting through the inhibition of cyclooxygenase [7].
Moreover, the great importance of COX-2 in PCOS is
apparent from its proliferative effect on the theca layer
cells of the ovary, where ovulation occurs. The direct
and indirect roles of COX-2 (through TNF-alpha) in
the thickening of the theca layer of the ovary have been
reported [9]. We demonstrated that COX-2 was overex-
pressed in PCOS rats [10]. However, the role of COX-2
overexpression during mammalian ovary cycles is still
less well defined. These findings correspond with a
common evolutionary background for PCOS, metabolic
and inflammatory disorders.
Angiogenesis induced by either endogenous COX-2
or exogenous prostaglandins (PGs) is accompanied by
increased expression of VEGF [11]. VEGF expression is
up-regulated by COX-2-mediated PGs [12]. Treatment of
the cells overexpressing COX-2 with a COX-2-selective
inhibitor also decreased PGE2 level and attenuated VEGF
expression [13].
Interleukin-6 (IL-6) is produced mostly by macrophages
and also by adipocytes. In PCOS patients circulating
levels of tumor necrosis factor-alpha (TNF-alpha), IL-6,
C-reactive protein (CRP), as well as white blood cells
(WBCs) and neutrophils have been found to be elevated
compared with controls [14-16].
Bee venom is comprised of a large number of pharma-
ceutical components, most notably melittin, apamin, adola-
pin and peptide 401, which have been widely investigated
to reveal their physiological effects, and to discover their
compatibility with different anti-inflammatory mechanisms.
The reduced expression of COX-2 and phospholipase
(PL) A2 and the decreased levels of tumor necrosis factor
alpha (TNF-alpha), IL-1, IL-6, nitric oxide (NO) and
reactive oxygen species (ROS) are suggested as being
associated with the anti-inflammatory effects of HBV
in some tissues [17-20].
In the present study, we have provided evidence for a
direct involvement of inflammation in the maintenance
and progression of PCOS. Clinical observations also
suggest that PCOS is associated with inflammation and
proliferation of circulating inflammatory molecules such
as IL-6, COX-2 and VEGF. According to the anti-
inflammatory effects of HBV on arthritis and some of
the inflammatory diseases, we hypothesize that HBV
decreases the incidence of PCOS, as an inflammatory
disease. To test this hypothesis, firstly we evaluated the
serum IL-6 levels, ovarian COX-2 and VEGF expressionin normal rats; and then to assess the close relationship
between PCOS, systemic inflammation and metabolic
syndrome, we compared these factors in normal rats
with PCOS animals; and finally, to discover the anti-
inflammatory effects of HBV, we investigated alterations
in these inflammation indexes, and eventually, the hormo-
nal and histological changes of ovary in HBV-treated rats
compared with PCOS ones.
Methods
Adult female Wistar rats weighing 170 ± 20 g (7–8 weeks
of age) from the animal house of the Kharazmi University,
Tehran, Iran, were kept in a central animal care facility,
housed in plastic cages (30 × 19 × 13 cm) under a 12-hour
light, 12-hour dark cycle (lights on from 6:00 to 20:00).
Humidity and temperature were set at 55 ± 15% and 20
to 24°C, respectively, and free access to water and com-
mercial food (Behparvar Com., Iran) was provided. All
procedures were carried out according to the Guidelines
for the Care and Use of Laboratory Animals (National
Research Council, 1996).
In this experiment, adult female Wistar rats with a
2–3 regular estrous cycle period within a twelve- to
fourteen-day period were used. PCOS rats were selected
on the basis of displaying a minimum of two continuous
estrous cycles. Rats were in the estrous stage of their
reproduction cycle.
Iranian honeybee venom was collected from Apis
mellifera by means of an electric shocker apparatus
composed of a shocker and a collector unit. The shocker
unit produces a light electric shock once every few
seconds. Honeybees were stimulated with light electric
shock and sting in beehives. The collector unit is a
network of wires with small gaps and a glass plane
between them. Every 25 minutes, the shocker unit turned
off and the dried bee venom material on collector panel
was collected by scraping.
Initially, animals were divided into three groups: controls
(no injection), PCOS [2 mg injection SC of estradiol
valerate (Aburaihan Co., Iran)] and sham 1 (a similar dose
of sesame oil with no estradiol content), with n = 8 for all
groups. All animals were under vaginal smear analysis
for a period of 60 days until the appearance of persistent
vaginal cornification (PVC), a sign of follicular cysts in
the ovary. After verifying the induction of PCOS, the
PCOS group was divided into two subgroups, PCOS
and PCOS +HBV. PCOS +HBV received 0.5 mg/kg HBV
IP for 14 consecutive days, while PCOS (i.e., sham 2)
group received physiological saline solution. Sham 1 and
sham 2 groups were later removed from the experiment
due to their lack of any difference with the control.
At around 9:00 am rats were anesthetized with CO2,
trunk blood was collected, and serum samples were
separated by centrifugation at 6,000 rpm for five minutes.
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ments. Fatty tissue was separated under a loop microscope.
Ovaries were separated from the twisted oviduct tubes.
Ovarian samples for immunohistochemical experiments
were fixed in formalin, embedded in paraffin, sectioned,
and mounted on glass slides. Twelve serial sections
(5-mm thickness) from each sample were prepared for
immunohistochemistry.IL-6 assay
Serological analysis was performed to measure serum
IL-6 levels and hormonal alterations. In order to detect
serum IL-6, an ELISA kit (rat IL-6 platinum ELISA®,
Bender Medsystems, Austria) was used according to the
manufacturer’s instructions. The assay was performed in
triplicate according to the manufacturer’s recommended
procedures. The results were expressed as mean ± SD
(pg/mL) of three individual rats. The sensitivities of the




















Figure 1 Honeybee venom treatment effects on levels of IL-6
production (pg/mL) in polycystic ovarian syndrome (PCOS).
Baseline parameters of PCOS rats (n = 8), control (n = 8) and bee
venom-treated rats (n = 8). *** p < 0.001 ** p < 0.01 vs. control.Immunohistochemistry
Sections of 5 mm in thickness were cut from formalin-
fixed tissue embedded in paraffin blocks and mounted
onto coated slides. Sections were de-waxed in xylene and
rehydrated in a graded alcohol series (100, 90, 70 and
50%). After deparaffinization, sections were boiled in
citrate buffer (0.05 M) in a microwave oven to reveal
antigens. Endogenous peroxidase was quenched with
3% (v/v) hydrogen peroxide (ten minutes at room
temperature). Samples were rinsed three times for five
minutes in PBS, and nonspecific binding was blocked
with dehydrated nonfat milk (50 mg/mL diluted in PBS).
Thereafter, tissue sections were rinsed three times
with 0.05% PBST ween-20 (PBS-T) and then incubated
overnight at 4˚C with rabbit and goat polyclonal anti-
body for VEGF and COX-2 (1:1000 and 1:500 dilution,
Abcam, UK). After being washed four times with PBS-T,
sections were incubated with anti-rabbit and anti-goat
secondary antibody (Bethyle Laboratories, Inc., USA,
and Universal LSAB™ + Kit/HRP, Rabbit/Mouse/Goat,
Product n K0690) for 90 minutes, at 1:300 dilution and
37˚C to amplify the signal. Following three washes in
PBS, sections were incubated with immunoreactivity
complexes detected by 3, 3’-diaminobenzidine tetrahy-
drocholoride (Immunohistochemistry Accessory Kit, Bethyl
Laboratories Inc., USA). Slides were then counterstained
with Mayer’s hematoxylin and mounted on crystal (entel-
lan). Negative controls were included in each experiment
by incubating tissue sections with antibody dilution buffer
instead of the primary antibody. Positive control slides
consisted of rat hippocampus cells for COX-2 and vessels
for VEGF.Immunohistochemical evaluations
The H-score is the sum of the proportion of cells showing
different degrees of reactivity. For H-score assessment,
ten fields were chosen at random at 400× magnification
and the staining intensity of each slide was scored as 0,
1, 2 or 3 corresponding to the presence of negative, weak,
intermediate or strong brown staining, respectively. The
total number of cells in each field and the number of
cells stained at each intensity were counted. The average
percentage positive was calculated and the following
formula was applied:
H ‐ score = [(% of cells stained at intensity category 1) ×
1] + [(% of cells stained at intensity category 2) × 2] +
[(% of cells stained at intensity category 3) × 3]
An H-score between 1 and 300 is obtained, in which
300 is equal to 100% of cells stained strongly. The raw data
were converted to Quick score values by multiplying the
quantity and staining intensity scores.
Statistical analysis
All statistical analyses were performed with INSTAT
version 3.0 software. The differences in immunohisto-
chemistry and area of positive staining were evaluated
using the analysis of variance (ANOVA). Data were
expressed as means ± standard error (SEM), and the
results were taken from at least three independent
experiments, performed in triplicate. Values of p of 0.05
or less were considered statistically significant.
Results
In addition to a significant increase in body weight of
the PCOS group, an increase in adipose tissue of the
abdominal cavity was macroscopically detected. On the
other hand, the decreases in both abdominal adipose
tissue and total body weight detected macroscopically
in the HBV-treated group were not significant [21].
A significant increase in the weight of the ovaries
was detected in the PCOS group compared to controls.
Figure 2 Expression of COX-2 in primary and secondary follicles. (A) normal ovary; (B) strict expression of COX-2 is observable in these folli-
cles in PCOS group; (C) COX-2 expression is restricted to blood vessels and ovary stroma (filled arrow) in HBV group. Magnification 100 × .
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nificant decrease in ovary weight compared to PCOS.
Chemiluminescent immunoassay (CLIA) showed a sig-
nificant increase in the levels of both testosterone and
estradiol in the PCOS group. However, progesterone
levels did not decrease significantly. These three hormones
were diminished in animals treated with bee venom. The
reduction observed in testosterone and estradiol levels
in HBV-treated animals were significant. Progesterone
levels differed significantly between the HBV-treated
compared to the polycystic group, which was due to
formation of corpora lutea in the ovaries of the former.
These data, in particular the increase in androgen (i.e.,
testosterone) levels, demonstrate the success of PCOS
induction, and that bee venom was able to reduce
estradiol and testosterone levels.
A significant decrease was observed in the number of
primary follicles, antral follicles, corpora lutea, primor-
dial follicles and preantral follicles in PCOS ovaries. In
addition, some large cystic follicles with a thin granulosa
of 2–3 cell layers were observed. In this group, no corpus
luteum, as a sign of ovulation, was detected. In the sham
group, ovaries contained no cyst but several follicles at
different stages of development, and also corpora lutea,
were distinguishable. These results were indicative of a
complete induction of the PCOS phenotype. In rats treated
with HBV, the number of primordial and preantral follicles
and corpora lutea increased, whereas the number of cystsFigure 3 Expression of COX-2 in infolded layers and follicular liquid o
granulosa and theca layers in control group. (B) Due to high levels of angi
are high. The thick theca and granulosa layers indicate high expression lev
decrease in expression levels of COX-2 in HBV group. Arrows depict the prdecreased significantly compared to the sham group.
In addition, some corpora lutea were observed in the
HBV group, which was considered a sign of relative
improvement in PCOS ovaries [10].
IL-6 assay
In this study, PCOS induction led to a significant rise in
IL-6 inflammatory index (p < 0.001 vs. control rats). The
effect of HBV (0.5 mg/kg) on the level of IL-6 in PCOS
rats was examined for 14 days after complete induction
of PCOS. As shown in Figure 1, the respective IL-6
levels in control, PCOS and HBV-treated PCOS rats
were 24, 150 and 46 pg/mL. The IL-6 level in HBV-treated
rats was reduced by p < 0.01 vs. PCOS rats. Results showed
that administration of HBV (0.5 mg/kg) significantly
reduced the IL-6 level in comparison with that in the
PCOS group (Figure 1).
VEGF and COX-2 expression
Expression of VEGF protein was detected by immuno-
histochemistry in all of the specimens examined. The
PCOS group presented strong immunoreactivity to COX-2
and VEGF was observed in theca layers and consequently
in follicular fluid, and some VEGF expression was seen
in the granulosa layer, although not as consistently as
in theca cells. Diffuse, usually weak expression was seen
in ovarian stroma, within individual cells. COX-2 and
VEGF expression in stromal cell in the HBV-treatedf Graafian follicles and cysts. (A) Low expression of COX-2 is seen in
ogenesis, the density of follicular liquid, as well as COX-2 expression
els of COX-2 in PCOS group. (C) A cyst is distinguishable, with no
edominant location of COX-2. Magnification 100 × .
Figure 4 Expression of VEGF in infolded layers and follicular liquid of Graafian follicles and cysts. (A) VEGF is highly expressed in theca
layer of ovaries, whereas, this high expression is not seen in granulosa layer of antral follicles in control group. (B) High expression of VEGF is
observable in granulosa and theca layers in PCOS group. (C) VEGF is just expressed in theca layer, especially in blood vessels of venom-treated
ovaries. Arrows depict the predominant location of VEGF in theca layer. Magnification 100 × .
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immunostaining in the theca layer in HBV-treated
PCOS group was less intense than in PCOS group. In
the HBV-treated PCOS group, COX-2 presented low
expression in granulosa and theca layers in preantral
follicles and no expression in the primary and secondary
follicles. These staining patterns were similar to the ovaries
of healthy control group, in which VEGF expression was
limited to stroma and theca layer and COX-2 expression
limited to granulosa and theca layer of Graafian follicle
(Figures 2, 3, 4, 5, 6, 7).Figure 5 Negative and positive controls for COX-2 and VEGF. Negative
sections with antibody dilution buffer instead of the primary antibody (ant
cells for COX-2 (left panel) and vessels of corpus luteum for VEGF (right panDiscussion
PCOS is a consequence pathway between IL-6, CRP,
TNF-alpha, androgens, COX-2 and VEGF: PCOS, as a
proinflammatory state, is evidenced by elevated plasma
concentrations of a number of inflammatory mediators
such as IL-6 [16,22]. IL-6 stimulates C-reactive protein
synthesis in the liver [23]. Consequently, CRP induces
secretion by p38 MAPK-TLR4 signal pathway in rat
vascular and adipose cells [24,25]. According to an in-
vestigation by Spaczynski et al. [26], TNF-alpha causes
proliferation and differentiation of theca cells andcontrols were included in each experiment by incubating tissue


























Figure 6 Quick score analysis of COX-2 immunostaining in con-
trol, PCOS, and HBV-treated ovary. Results were expressed as
mean ± SEM from n = 8. ***p < 0.001, **p < 0.01, *p < 0.05 vs. control.
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cells. Additional migration of mononuclear cells
(MNC) into adipose tissue in PCOS models and their dif-
ferentiation into macrophages (releasing other cyto-
kines) in stroma visceral parts result in the activation of
adipocyte TNF-alpha production [27].
TNF-alpha induces insulin resistance in endothelial
cells and activates NF-kB/NFIL6/CRE through PKC/
MAP kinase/JNK/P38 signaling pathways and thereupon
provokes an increase in the expression of cyclooxygenase
2 (COX-2) [28-30]. Invading macrophages up-regulate
COX-2 and prostaglandin E2 (PGE2) suggesting that
PGE2 may affect macrophage function via autocrine or
paracrine mechanisms. Colocalization of IL-6 with COX-2
was frequently observed. PGE2 has been shown to fa-
cilitate cell survival and induce the production of IL-6
in peritoneal macrophages in vitro [8].
The elevated expression of COX-2 and VEGF in theca
layer of ovary causes an augmentation in the diameter
of this layer, due to their ability to stimulate cell pro-


























Figure 7 Quick score analysis of VEGF immunostaining in
control, PCOS, and HBV-treated ovary. Results were expressed as
mean ± SEM from n = 8. ***p < 0.001, **p < 0.01 vs. control.Androgens can lead to increased levels of lipolysis
and free fatty acids. Free fatty acids are primary ligands
for toll-like receptors, which are central regulators for
innate immune responses. Therefore, free fatty acids act as
direct links between hyperandrogenism and inflammation
[14]. This is the reason why we can consider cytokine
expression (IL-6) as an important factor in PCOS as a
low-grade chronic inflammation disease [16,22]. Thus, we
infer that increasing androgens as a confirming sign of
PCOS led to increases in IL-6, COX-2 and VEGF, which
we have considered.
In PCOS, hyperandrogenism and hyperglycemia may
be capable of promoting inflammation. They are able to
generate reactive oxygen species (ROS) from peripheral
blood mononuclear cells. ROS-induced oxidative stress
activates nuclear factor κB (NFκB), which is involved
in expression of COX-2 and induction of IL-6 [27,31].
Furthermore, the association of plasma inflammatory
mediators with circulating androgens can contribute
significantly to the promotion of PCOS.
With regard to an increase in serum IL-6 overexpression
of tissue COX-2 and VEGF as inflammatory signs in
our PCOS rats, PCOS may be analyzed considering its
inflammatory and metabolic aspects. If we consider PCOS
as an inflammatory disorder, we can decrease androgens
and the incidence of PCOS mediated by the bee venom.
Various mechanisms have been reported in recent
studies on anti-inflammatory and/or anti-arthritis action
of HBV and its components [17,18,32]. The anti-arthritis
effects of melittin, an HBV constituent, are suggested to
be decrease in COX-2 and phospholipase A2 expression
and decline in the levels of TNF-alpha, IL-1, IL-6 and
ROS. Anti-inflammatory activity has also been reported
by adolapin, an HBV constituent, in carrageenan-induced
edema, polyarthritis rats and PG-induced rat inflammation
[32]. Inhibiting the PG synthesis system through COX-2
inhibitory properties is considered to be the action
mechanism of adolapin. COX-2 activity and COX-2
mRNA expression are strongly inhibited by HBV in
a dose-dependent manner, and present no cytotoxic
effects. The inhibitory effect of HBV was comparable
to indomethacin, a well-known COX-2 inhibitor [19].
It is also reported that HBV is probably an effective
RA modulator, thus hindering the protease activity and
ROS removing. HBV indirectly decreases the expression
of COX-2 by reducing the amount of TNF-alpha, whereas
TNF-alpha activates NF-κB/NFIL6/CRE by PKC/MAP
kinase/JNK/P38 signaling pathways and consequently
provokes an increase in COX-2 expression. C-reactive
protein and VEGF levels were significantly lower in
groups given HBV therapy compared to the control
group [10,32,33].
Kim et al. [32] speculated that HBV produced a decreased
incidence of arthritis via its inhibitory effect on immune
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formation, and helps to modify the clinical condition of
the patient with rheumatoid arthritis [33].
Bee venom inhibits the DNA-binding activation of
NF-kB by inhibiting I-kB phosphorylation. The free and
active NF-kB, by the phosphorylation of I kB, is translo-
cated to the nucleus, where it binds to the kB binding
sites in the promoter regions of target inflammatory
genes and controls their expression.
Thus, our findings are in agreement with those of
others showing that the anti-inflammatory activity of
honeybee venom is mediated through suppression of the
NF-κB signaling pathway [18]. Therefore, increased levels
of androgens, IL-6, COX-2 and VEGF can be adjusted by
treating rats with HBV for 14 days and bee venom by
inhibitory effects on inflammatory index causes regression
of PCOS in this animal model [27]. Histological changes
observed in the ovary after bee venom treatment may
also be considered confirmation of recovery from this
syndrome. Our results confirm that bee venom causes
a decrease in the follicular theca layer in PCOS rats,
which is actually due to decreased ovarian angiogenesis.
Due to this decrease, the androgens and steroids produced
by this layer also decreased and consequently the total
levels of serum estrogen and androgens reduced.
Conclusions
Based on the results presented in this study, we can con-
clude that anti-inflammatory effects of HBV can restore
metabolic and reproductive features of PCOS. Decreased
levels of IL-6, COX-2, VEGF and serum androgens, and
increased number of corpora lutea are suggestive of
therapeutic effects of HBV on PCOS. We have established
that this effect of HBV is mediated by suppression of
inflammatory and angiogenic factors.
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